Artiva Biotherapeutics to shut down after two patient deaths in trial

• Artiva Biotherapeutics announced it is shutting down after two deaths in a cell therapy trial.
• One participant died from a neurological complication after receiving NK cell therapy.
• The company will cut its workforce by 94% as part of the winding down process.
• The trial was a Phase 2 study for treating autoimmune diseases.
• The decision follows a series of safety events in the cell therapy research field.